Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Unternehmen & Branche
| Name | Emergent BioSolutions Inc. |
|---|---|
| Ticker | EBS |
| CIK | 0001367644 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 29089q105 |
|---|---|
| ISIN | US29089Q1058 |
| Typ | Common Stock |
| Marktkapitalisierung | 434,1 Mio. USD |
| Beta | 2,36 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 742,900,000 | 52,600,000 | 0.93 | 1,318,600,000 | 522,600,000 |
| 2025-09-30 | 10-Q | 231,100,000 | 51,200,000 | 0.91 | 1,461,000,000 | 582,500,000 |
| 2025-06-30 | 10-Q | 140,900,000 | -12,000,000 | -0.22 | 1,417,100,000 | 536,200,000 |
| 2025-03-31 | 10-Q | 222,200,000 | 68,000,000 | 1.19 | 1,426,100,000 | 552,700,000 |
| 2024-12-31 | 10-K | 1,043,600,000 | -190,600,000 | -3.60 | 1,389,700,000 | 482,800,000 |
| 2024-09-30 | 10-Q | 293,800,000 | 114,800,000 | 2.06 | 1,477,800,000 | 508,400,000 |
| 2024-06-30 | 10-Q | 254,700,000 | -283,100,000 | -5.38 | 1,513,500,000 | 386,300,000 |
| 2024-03-31 | 10-Q | 300,400,000 | 9,000,000 | 0.17 | 1,803,600,000 | 663,900,000 |
| 2023-12-31 | 10-K | 1,049,300,000 | -760,500,000 | -14.85 | 1,823,200,000 | 649,300,000 |
| 2023-09-30 | 10-Q | 270,500,000 | -263,400,000 | -5.08 | 1,893,100,000 | 697,200,000 |
| 2023-06-30 | 10-Q | 337,900,000 | -261,400,000 | -5.16 | 2,178,800,000 | 957,700,000 |
| 2023-03-31 | 10-Q | 164,300,000 | -186,200,000 | -3.71 | 2,949,800,000 | 1,204,100,000 |
| 2022-12-31 | 10-K | 1,117,500,000 | -211,600,000 | -4.22 | 3,166,300,000 | 1,387,700,000 |
| 2022-09-30 | 10-Q | 239,900,000 | -87,100,000 | -1.75 | 2,895,700,000 | 1,433,000,000 |
| 2022-06-30 | 10-Q | 242,600,000 | -52,900,000 | -1.06 | 2,735,400,000 | 1,508,300,000 |
| 2022-03-31 | 10-Q | 304,800,000 | -4,600,000 | -0.09 | 2,780,400,000 | 1,566,900,000 |
| 2021-12-31 | 10-K | 1,773,600,000 | 219,500,000 | 4.06 | 2,959,000,000 | 1,611,500,000 |
| 2021-09-30 | 10-Q | 329,000,000 | -32,700,000 | -0.61 | 2,867,500,000 | 1,522,700,000 |
| 2021-06-30 | 10-Q | 397,500,000 | 4,600,000 | 0.09 | 2,915,200,000 | 1,543,700,000 |
| 2021-03-31 | 10-Q | 343,000,000 | 69,700,000 | 1.28 | 2,900,100,000 | 1,522,800,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Ancora Advisors LLC | 170,469 | 0 | 170,469 | 2,106,997 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | DeGolyer Donald W | Director | Open Market Sale | -14,527 | 8.36 | -121,445.72 | -102,8% | |
| 2026-05-01 | Zoon Kathryn C | Director | Open Market Sale | -1,057 | 8.97 | -9,481.29 | -8,0% | |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Open Market Sale | -980 | 8.94 | -8,761.20 | -7,4% | |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Open Market Sale | -12,781 | 8.36 | -106,849.16 | -90,4% | |
| 2026-05-01 | DeGolyer Donald W | Director | Open Market Sale | -954 | 8.96 | -8,547.84 | -7,2% | |
| 2026-05-01 | Zoon Kathryn C | Director | Open Market Sale | -16,145 | 8.36 | -134,972.20 | -114,2% | |
| 2026-04-30 | Katkin Keith | Director | Open Market Sale | -15,481 | 8.28 | -128,182.68 | -108,5% | |
| 2025-12-05 | Richard Ronald | Director | Open Market Sale | -14,884 | 11.90 | -177,086.86 | -149,9% | |
| 2025-12-05 | Richard Ronald | Director | Open Market Sale | -7,100 | 12.11 | -85,990.23 | -72,8% | |
| 2025-11-10 | DeGolyer Donald W | Director | Open Market Sale | -17,801 | 10.54 | -187,622.54 | -158,8% | |
| 2025-11-07 | Dayal Sujata Tyagi | Director | Open Market Sale | -8,552 | 10.00 | -85,520.00 | -72,4% | |
| 2025-10-07 | Glessner Coleen | Officer, EVP, Quality & Ethics, and CPL | Open Market Sale | -30,608 | 10.00 | -306,080.00 | -259,1% | |
| 2025-08-15 | Zoon Kathryn C | Director | Open Market Sale | -7,086 | 8.87 | -62,852.82 | -53,2% | |
| 2025-08-12 | DeGolyer Donald W | Director | Open Market Sale | -7,844 | 8.65 | -67,830.99 | -57,4% | |
| 2025-05-23 | Katkin Keith | Director | Open Market Sale | -7,844 | 6.30 | -49,417.20 | -41,8% | |
| 2025-05-13 | PAPA JOSEPH C | Director, Officer, President and CEO | Open Market Purchase | 60,000 | 5.83 | 349,800.00 | +296,1% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Ancora Advisors LLC | 170,469 | 2,106,997 | 100.00 |